Introduction. The coronavirus pandemic has affected millions worldwide. Better understanding of COVID-19 inpediatric hematology-oncology patients in a resource-limited setting is crucial to improve care as the pandemicensues. Objectives. This study describes the clinical profile and outcomes of pediatric hematology oncology patients with COVID-19 seen at the Philippine General Hospital (PGH). Methods. A retrospective, descriptive review of pediatric hematology oncology patients with COVID-19 seenbetween March 2020 to March 2021 in PGH was done. Results. Forty patients were identified. Seventeen percent had non-malignant hematologic conditions, 40% hadleukemias, and 42.5% had solid tumors. Fever and cough were the most common manifestations. Seventy-sixpercent were on treatment, 9% were newly diagnosed, and 7% were in relapse or disease progression. Fifty-fivepercent had mild COVID-19; 5% and 2.5% had severe and critical COVID-19, respectively. Thirty-seven percentwere asymptomatic. Cancer-related therapy was placed on hold for most patients. There were two mortalities, none was due to COVID-19. Conclusion. Results suggest that patients with hematologic and oncologic conditions have a mild course, withmajority showing recovery from COVID-19. Delays in cancer-related therapy however, may contribute to diseaseprogression and mortality.
No takes yet. Share an insight, caveat, or question.
Ong et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: